Because ERα is expressed in 70% of breast cancers [16], and the proliferation of these ERα-positive breast cancers is largely dependent on estrogen/ERα signaling [17], the endocrine therapy that targets estrogen/ERα signaling has been well established as an effective adjuvant treatment for patients with ERα-positive breast cancers [18]. Here, ESR1 is linked to breast carcinoma.